AMD says its latest Instinct MI300X graphics processing units, running on the company's ROCm software platform, can speed up DNA alignment by up to 1.78 times compared to previous hardware. The performance boost, detailed in a company announcement, pushes genomics one step closer to real-time analysis — a milestone that could reshape how quickly researchers identify genetic variants and diagnose diseases.
What the MI300X Brings to Genomics
The MI300X is AMD's flagship GPU for high-performance computing and AI workloads. It combines CPU and GPU cores in a single package and is designed to handle massive parallel processing tasks. For genomics, the key metric is DNA alignment — the process of mapping short DNA sequences (reads) against a reference genome. This step is computationally intensive and often a bottleneck in workflows. AMD claims its new hardware, paired with the ROCm open-source software stack, delivers a 1.78x speedup over the previous generation for this specific task.
The company didn't disclose the exact benchmark conditions or which competing hardware it compared against. But the figure suggests a meaningful leap for labs that process large volumes of sequencing data. Faster alignment means researchers can analyze more samples in less time, or run deeper analyses on existing data.
The Role of ROCm
ROCm is AMD's answer to Nvidia's CUDA platform — a set of tools and libraries that let developers tap into GPU acceleration without writing low-level code. For genomics, ROCm includes optimized libraries for common bioinformatics algorithms. AMD has been pushing ROCm as an open alternative, and the MI300X is its most powerful chip to run it. The company says the combination of hardware and software is what enables the 1.78x speedup, not just raw compute power.
That matters because many genomics tools are written for CUDA and need to be ported to ROCm. AMD has been working with the open-source community to make that transition smoother. The company's claim suggests that for DNA alignment at least, the porting effort is paying off.
Real-time genomics — where a patient's genome is sequenced and analyzed in hours rather than days — is a long-standing goal. Faster alignment is one piece of that puzzle. If the MI300X can cut alignment time by nearly half, it could help labs move closer to that target. But alignment is just one step; variant calling, annotation, and interpretation also need to speed up.
AMD hasn't said when the MI300X will be widely available for genomics workloads, or how much it will cost. The company is likely targeting both cloud providers and on-premise research clusters. For now, the 1.78x claim stands as a benchmark for what the hardware can do — and a challenge to competitors to match it.
